TY - JOUR
T1 - Prognostic effect of liver metastasis in lung cancer patients with distant metastasis
AU - Ren, Yijiu
AU - Dai, Chenyang
AU - Zheng, Hui
AU - Zhou, Fangyu
AU - She, Yunlang
AU - Jiang, Gening
AU - Fei, Ke
AU - Yang, Ping
AU - Xie, Dong
AU - Chen, Chang
N1 - Funding Information:
Supported by the grants from the National Natural Science Foundation of China (No.81570014) and the projects from Science and Technology Commission of Shanghai Municipality (No.15JC1490900, No.14411962600, No.13DZ1942805 and No.15695840600) and Health and Family Planning Commission of Shanghai Municipality (No.2013ZYJB0003), and Pujiang Project (15PJD034).
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Because the need of clinical prognostic evaluation by specific metastatic organ, we aim to analyze the prognostic factors in lung cancer patients with M1b disease with Surveillance Epidemiology and End-Results database (SEER). This retrospective study evaluated lung cancer patients of adenocarcinoma (AD), squamous cell carcinoma (SQCC), and small cell lung cancer (SCLC) selected from SEER. We provided the prognostic correlates of overall survival (OS) and lung cancer-specific survival (LCSS) in this population. 23,679 eligible patients were included. Bone was the most common metastatic site in AD (63.1%) and SQCC (61.1%), while liver was the most prevalent site (61.9%) in SCLC. Single site metastasis was significantly associated with better outcome compared to multiple sites metastases in all patients. Among patients with single site metastasis, OS and LCSS were longer for AD and SCLC if involving brain or bone, with median survival time of 5 to 7 months, comparing to 3 months if invloving liver (all p-values < 0.001). Similarly, among patients with multiple metastases, better outcomes were observed in AD patients (4 vs 3 months; OS and LCSS, p < 0.001) and SCLC patients (6 vs 4 months; OS, p = 0.017; LCSS, p = 0.023) without liver metastasis compared to those with liver metastasis. In conclusion, we estimated multiple survival outcomes by histology of primary tumor and sites of metastasis. Liver metastasis is found to be the worst prognostic factor for AD and SCLC patients with distant metastasis. More in-depth research is warranted to identify patients who are prone to develop distance metastasis, especially to liver.
AB - Because the need of clinical prognostic evaluation by specific metastatic organ, we aim to analyze the prognostic factors in lung cancer patients with M1b disease with Surveillance Epidemiology and End-Results database (SEER). This retrospective study evaluated lung cancer patients of adenocarcinoma (AD), squamous cell carcinoma (SQCC), and small cell lung cancer (SCLC) selected from SEER. We provided the prognostic correlates of overall survival (OS) and lung cancer-specific survival (LCSS) in this population. 23,679 eligible patients were included. Bone was the most common metastatic site in AD (63.1%) and SQCC (61.1%), while liver was the most prevalent site (61.9%) in SCLC. Single site metastasis was significantly associated with better outcome compared to multiple sites metastases in all patients. Among patients with single site metastasis, OS and LCSS were longer for AD and SCLC if involving brain or bone, with median survival time of 5 to 7 months, comparing to 3 months if invloving liver (all p-values < 0.001). Similarly, among patients with multiple metastases, better outcomes were observed in AD patients (4 vs 3 months; OS and LCSS, p < 0.001) and SCLC patients (6 vs 4 months; OS, p = 0.017; LCSS, p = 0.023) without liver metastasis compared to those with liver metastasis. In conclusion, we estimated multiple survival outcomes by histology of primary tumor and sites of metastasis. Liver metastasis is found to be the worst prognostic factor for AD and SCLC patients with distant metastasis. More in-depth research is warranted to identify patients who are prone to develop distance metastasis, especially to liver.
KW - Distant metastasis
KW - Lung cancer
KW - Prognosis
KW - Surveillance epidemiology and end-results database
UR - http://www.scopus.com/inward/record.url?scp=84982273209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982273209&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.10644
DO - 10.18632/oncotarget.10644
M3 - Article
C2 - 27449299
AN - SCOPUS:84982273209
SN - 1949-2553
VL - 7
SP - 53245
EP - 53253
JO - Oncotarget
JF - Oncotarget
IS - 33
ER -